Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.02 +1.23%

+$0.04 today

Market cap
$220.03M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 5.46M

Average 3.33M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$131.08M

FY 2025 · Annual

Investing Cash Flow

-$50.27M

FY 2025 · Annual

Financing Cash Flow

$100.35M

FY 2025 · Annual

+759.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
Deferred Income Tax00000
Stock-Based Compensation5.8M6.9M11.34M19.47M20.94M
Change in Working Capital5.58M(4.3M)101K1.61M(379K)
Accounts Receivables00000
Inventory00000
Accounts Payables975K(28K)1.68M1.01M1.55M
Other Working Capital4.61M(4.27M)(1.57M)600K(1.93M)
Other Non-Cash Items62K2.82M1.26M4.86M14.57M
Operating Cash Flow(34.11M)(46.38M)(53.55M)(88.22M)(131.08M)
Capital Expenditures(1.17M)(2.45M)(687K)(2.21M)(1.23M)
Acquisitions (Net)024.76K000
Purchases of Investments0(49.76M)(84.26M)0(99.04M)
Sales of Investments7.17M25M62.5M49.5M50M
Other Investing Activities0(24.76K)000
Investing Cash Flow6M(27.22M)(22.45M)47.29M(50.27M)
Debt Repayment000(897K)(6.26M)
Common Stock Issued48.25M32.86M185.2M10.88M106.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities650K127K2.43M1.7M0
Financing Cash Flow48.9M32.98M187.63M11.68M100.35M
Effect of Forex Changes000(20K)19K
Net Change in Cash20.79M(40.62M)111.63M(29.28M)(80.98M)
Free Cash Flow(35.28M)(48.83M)(54.24M)(90.43M)(132.31M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$167.9M
+ D&A$1.6M
+ Stock-Based Comp$20.9M
+ Deferred Tax$0
- Working Capital-$379.0K
+ Other Non-Cash$14.6M
= Operating Cash Flow-$131.1M
- Capex-$1.2M
= Free Cash Flow-$132.3M

Analysis

FY2025 free cash flow is -$132.3M. FCF conversion is 78.8% of net income. Operating cash flow was -$131.1M, with capex of -$1.2M. The largest bridge item is Stock-Based Comp at $20.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 12, 2026
8-KCurrent reportNov 9, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
8-KCurrent reportNov 5, 2026

Does CABA generate free cash flow?

Cabaletta Bio, Inc. (CABA) generated -$132.31M of free cash flow in fiscal 2025.

How much operating cash flow does CABA produce?

Operating cash flow was -$131.08M, before capital expenditures of $1.23M.